Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy

Inclusion Criteria: * Patients voluntarily join the study, signed informed consent, good compliance; * The pathology was diagnosed as stage Ⅳ soft tissue sarcoma patients, clinical staging using the American Cancer Research Joint Committee (AJCC) TNM staging criteria. According to CT or MRI at least one measurable lesion; * At least one chemotherapy regimen (containing anthracycline) was treated and evaluated as "disease progression" in terms of the efficacy evaluation criteria of solid tumors (RECIST 1.1). * 18 to 70 years old, PS score: 0 \~ 2; expected survival period of more than 3 months; * The laboratory check meets the following criteria: * Blood routine examination: HB ≥ 100g / L (14 days without blood transfusion); ANC ≥ 1.5 × 109 / L; PLT ≥ 80 × 109 / L * Biochemical tests: serum creatinine Cr ≤ normal upper limit (ULN), bilirubin BIL ≤ normal upper limit (ULN), ALT, AST ≤ 1.5 × normal upper limit (ULN), for liver metastases ≤ 5 × normal upper limit (ULN); fasting triglyceride ≤ 3.0mmol / L, fasting cholesterol ≤ 7.75mmol / L; * Doppler ultrasonography: left ventricular ejection fraction (LVEF) ≥ normal low (50%). * Women should agree that contraceptive measures (such as IUDs, contraceptives or condoms) must be used within six months of the study period and after the end of the study; serum or urine pregnancy studies were negative for 7 days prior to study , and must be non-lactating patients; men should agree that contraceptive measures must be used within six months of the study period and after the end of the study period. Exclusion Criteria: * Patients who have received antiangiogenic therapy or other targeted treatment for no more than 3 months, such as Endostar, Erlotinib, Sunitinib, Sorafenib, Avastin, Imatinib, Famitinib, Pazopanib and other drugs. * Past or concurrent with other malignancies, except for cured skin basal cell carcinoma and cervical in situ cancer; * Participated in other drug clinical researchers within four weeks; * Previously received anticancer treatment patients with NCI CTC AE grade\> 1 grade toxicity; * Have a variety of factors that affect oral medication (such as can not swallow, gastrointestinal resection, chronic diarrhea and intestinal obstruction, etc.) * Known brain metastases, spinal cord compression, cancerous meningitis, or screening when the CT or MRI examination found that the brain or pia mater disease; * Patients with any severe and / or uncontrolled disease, for example: * Unstable angina, symptomatic congestive heart failure, myocardial infarction within 6 months prior to randomization, severe uncontrollable arrhythmia; poor blood pressure control (systolic blood pressure\> 140 mmHg, diastolic blood pressure\> 90 mmHg )patient; * Active or uncontrollable serious infection; * Liver diseases such as cirrhosis, decompensated liver disease, chronic active hepatitis; * Poor control of diabetes (fasting blood glucose (FBG)\> 10mmol / L); * Urinary routine urinary protein ≥ ++, and confirmed 24 hours urine protein\> 1.0 g; * Long untreated wound or fracture; * Patients with bleeding tendency (such as active gastrointestinal ulcers) or treated with anticoagulants or vitamin K antagonists such as warfarin, heparin or analogues; * Interventional venous thrombosis events such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis, and pulmonary embolism before the first medication. * Have a history of psychiatric abuse and can not quit or have mental disorders; * Have a history of immunodeficiency, including HIV testing positive or other acquired, congenital immune deficiency disease, or a history of organ transplantation; * According to the researcher's judgment, there are serious illnesses that compromise the patient's safety or affect the patient's completion of the study.